Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 9/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541351 | 0.84 | FFAR2 (0.33) | CTSAFFAR1GPR139PDE2A | |
| SCHEMBL2548040 | 0.84 | GPR139 (0.35) | CTSAFFAR1NPC1RAB9AGPR139 | |
| SCHEMBL1743679 | 0.84 | GPR139 (0.35) | CTSAFFAR1NPC1RAB9AGPR139 | |
| SCHEMBL3706895 | 0.84 | GPR139 (0.35) | CTSAFFAR1NPC1RAB9AGPR139 | |
| SCHEMBL1595431 | 0.79 | PDE2A (0.39) | CNR2PDE2A | |
| SCHEMBL1595429 | 0.79 | PDE2A (0.39) | CNR2PDE2A | |
| SCHEMBL1743812 | 0.78 | CDK2 (0.33) | CTSAFFAR1 | |
| SCHEMBL2544780 | 0.75 | CNR2 (0.34) | FFAR1CNR2CNR1PDE2A | |
| SCHEMBL1744761 | 0.75 | CNR2 (0.34) | FFAR1CNR2CNR1PDE2A | |
| SCHEMBL12241693 | 0.74 | CTSK (0.37) | FFAR1GPR139PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | CTSA 3111/4885FFAR1 381/4885NPC1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.